Related Experiment Video

Updated: Sep 25, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K

Alphaviruses in Cancer Therapy

Kenneth Lundstrom1

  • 1Pan Therapeutics, Lutry, Switzerland.

Frontiers in Molecular Biosciences
|May 2, 2022
PubMed

Insights

Alphaviruses are engineered as effective cancer therapy vectors, showing promise in immunotherapy and vaccine development. Clinical trials demonstrate their potential in treating various cancers, including cervical, breast, and colon cancers.

Area of Science:

  • Oncology
  • Virology
  • Immunotherapy

Background:

  • Alphaviruses are versatile expression vectors utilized in cancer therapy.
  • Recombinant virus particles, RNA replicons, and DNA replicons offer flexible delivery strategies.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of alphavirus-based cancer therapies.
  • To assess the potential of alphavirus vectors in immunotherapy and cancer vaccine development.

Main Methods:

  • Engineering alphaviruses as expression vectors for cancer treatment.
  • Utilizing recombinant virus particles, RNA replicons, and DNA replicons for delivery.
  • Conducting immunization and delivery studies in animal models and clinical trials.

Main Results:

  • Demonstrated therapeutic efficacy in reducing tumor growth, inducing regression, and eradicating tumors in various animal cancer models.
  • Showed protection against tumor cell challenges in vaccinated animals.
  • Clinical trials indicated immune responses and therapeutic activity in cervical cancer patients, stable disease/partial responses in breast cancer patients, and prolonged survival in colon cancer patients.

Conclusions:

  • Alphavirus-based strategies show significant therapeutic potential for diverse cancers.
  • Clinical evidence supports the efficacy of alphavirus vaccines in eliciting immune responses and achieving clinical benefits.
  • Further clinical development of alphavirus vectors for cancer therapy is warranted.
Keywords:
DNA repliconRNA repliconcancer vaccineimmunotherapyrecombinant particlesself-replicating RNA

More Related Videos

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

13.4K
Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

9.5K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.3K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.5K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
528
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
682